Intuitive Surgical, Inc. appointed Aaron Martin as an independent director effective January 1, 2027, expanding its board from 10 to 11 members. He will receive an annual cash retainer of $70,000 and an initial restricted stock unit grant valued at $93,333.
ISRG · Intuitive Surgical Inc
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Intuitive Surgical had 2,023 installed da Vinci 5 systems and 487 da Vinci SP systems as of September 30, 2026; IEEPA tariff refunds reduced cost of revenue by $27.8 million and $63.7 million during the three and nine months ended September 30, 2026.
Intuitive Surgical Inc reported 22% revenue growth, 15% total procedure growth, and narrowed 2026 procedure-growth guidance to 14% to 15%. Pricing actions are expected to reduce DaVinci INA revenue per procedure by approximately 3% to 5% once fully implemented.
Intuitive Surgical reported third quarter 2026 revenue of $3.05 billion, up 22%, and GAAP net income of $523 million, or $1.49 per diluted share. The results included a $450 million antitrust settlement charge.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| da Vinci 5 systems placed | 315 | third quarter 2026 | — |
|
|
|||
| Da Vinci procedures | 14% | third quarter 2026 | — |
|
|
|||
| da Vinci surgical system installed base | 12,094 | as of September 30, 2026 | — |
| da Vinci surgical system placements | 546 | third quarter 2026 | — |
|
|
|||
| da Vinci surgical system placements under operating lease arrangements | 291 | third quarter 2026 | — |
| da Vinci surgical system placements under usage-based operating lease arrangements | 160 | third quarter 2026 | — |
| Ion endoluminal system installed base | 1,152 | as of September 30, 2026 | — |
| Ion endoluminal systems placed | 56 | third quarter 2026 | — |
| Ion procedures | 31% | third quarter 2026 | — |
|
|
|||
| Non-GAAP gross profit non-GAAP | $6.03B | Nine Months Ended September 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP GAAP gross profit $2.08B
+$36.6M Share-based compensation expense
+$0M Long-term incentive plan expense
+$8.7M Amortization of intangible assets
+$0M Acquisition-related items
= Non-GAAP gross profit $2.13B
|
|||
| Non-GAAP gross profit margin non-GAAP | 69.2% | Nine Months Ended September 30, 2026 | — |
| Non-GAAP income from operations non-GAAP | $3.56B | Nine Months Ended September 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP GAAP income from operations $592.6M
+$212.6M Share-based compensation expense
+$0.3M Long-term incentive plan expense
+$9.3M Amortization of intangible assets
+$0M Facilities asset abandonment charge
+$454.9M Litigation charges
+$0M Gains on sale of businesses and assets
+$0M Acquisition-related items
= Non-GAAP income from operations $1.27B
|
|||
| Non-GAAP net income attributable to Intuitive Surgical, Inc. non-GAAP | $2.96B | Nine Months Ended September 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP GAAP net income attributable to Intuitive Surgical, Inc. $522.8M
+$212.6M Share-based compensation expense
+$0.3M Long-term incentive plan expense
+$9.3M Amortization of intangible assets
+$0M Facilities asset abandonment charge
+$454.9M Litigation charges
+$0M Gains on sale of businesses and assets
-$0.9M (Gains) losses on strategic investments
+$0M Acquisition-related items
-$144.4M Tax adjustments (2)
-$0.1M Adjustments attributable to noncontrolling interest in joint venture
= Non-GAAP net income attributable to Intuitive Surgical, Inc. $1.05B
|
|||
| Worldwide procedures (da Vinci and Ion combined) | 15% | third quarter 2026 | — |
| % of Total da Vinci surgical system placements (under leasing) | 54% | Three Months Ended June 30, 2026 filing | — |
| % of Total revenue | 85% | Three Months Ended June 30, 2026 filing | — |
| da Vinci procedures performed | 889,000 | the three months ended June 30, 2026 filing | — |
| da Vinci surgical system ASP | $1.59M | the three months ended June 30, 2026 filing | — |
| IEEPA tariff refunds (product) | $27.5M | the second quarter of 2026 filing | — |
| IEEPA tariff refunds (service) | $8.4M | the second quarter of 2026 filing | — |
| Ion procedures performed | 47,900 | the three months ended June 30, 2026 filing | — |
| Ion systems placed | 55 | the three months ended June 30, 2026 filing | — |
| Lease Buyouts revenue | $56M | Three Months Ended June 30, 2026 filing | — |
| Operating lease revenue | $262M | Three Months Ended June 30, 2026 filing | — |
| OUS da Vinci procedure growth | 20% | Three Months Ended June 30, 2026 filing | — |
| Product gross profit margin | 67.9% | Three Months Ended June 30, 2026 filing | — |
| Service gross profit margin | 67.2% | Three Months Ended June 30, 2026 filing | — |
| Total da Vinci surgical system placements under leasing arrangements | 264 | Three Months Ended June 30, 2026 filing | — |
| Total Ion system placements under leasing arrangements | 31 | Three Months Ended June 30, 2026 filing | — |
| Total recurring revenue | $2.47B | Three Months Ended June 30, 2026 filing | — |
| U.S. da Vinci procedure growth | 12% | Three Months Ended June 30, 2026 filing | — |
| Variable lease revenue | $169M | Three Months Ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ISRG
this stock
Intuitive Surgical Inc
|
$151.74B | -22.7% | +20.5% | 53.1 | 2.0% |
|
BDX
Becton Dickinson & Co
|
$58.96B | — | +8.2% | 95.8 | 3.0% |
|
MDLN
Medline Inc.
|
$51.52B | -6.7% | +11.5% | — | 2.9% |
|
ALC
Alcon Inc
|
$35.38B | -6.6% | +10.5% | — | 3.8% |
|
RMD
Resmed Inc
|
$33.50B | -1.1% | +13.4% | 21.7 | 7.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 2, 2026
- This year
- 19
Intuitive Surgical, Inc. appointed Aaron Martin as an independent director effective January 1, 2027, expanding its board from 10 to 11 members. He will receive an annual cash retainer of $70,000 and an initial restricted stock unit grant valued at $93,333.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ISRG | -5.0% | +1.1% | +4.6% | +1.3% | -22.7% |
| SPY | -1.7% | -3.5% | -1.4% | -2.1% | +8.5% |
| vs SPY | -3.3% | +4.5% | +6.0% | +3.4% | -31.2% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.